Kentucky 2023 Regular Session

Kentucky House Bill HB180

Introduced
2/7/23  
Refer
2/7/23  
Refer
2/10/23  
Report Pass
2/16/23  
Engrossed
2/23/23  
Refer
2/23/23  
Refer
3/1/23  
Report Pass
3/8/23  
Enrolled
3/13/23  
Enrolled
3/13/23  
Chaptered
3/23/23  

Caption

AN ACT relating to coverage for biomarker testing.

Impact

The introduction of HB 180 will streamline the process for patients to access crucial biomarker tests covered by their health insurance, provided such tests meet the stipulated criteria. This mandatory coverage is expected to result in more informed treatment decisions, particularly for conditions such as cancer, where biomarker testing can identify suitable therapies for individuals based on their unique genetic makeup. The implications of this bill are significant as it not only improves patient outcomes but also aligns with emerging practices in personalized medicine by ensuring that the financial burden of these testing procedures does not fall on patients alone.

Summary

House Bill 180 seeks to improve healthcare provisions by mandating the coverage of biomarker testing under health benefit plans. Biomarker testing involves analyzing a patient's tissue or other biospecimens to obtain measurable indicators of biological processes and potential responses to therapies. This bill emphasizes the importance of using clinically validated tests to ensure that patients receive the necessary diagnostics and treatments in a timely manner, thereby enhancing the quality of care across the state. The provisions of this bill are set to take effect on January 1, 2024, impacting future insurance policies and practices as they pertain to biomarker testing.

Sentiment

The sentiment surrounding HB 180 appears to be predominantly positive, reflecting a growing recognition of the necessity for advanced medical testing in contemporary healthcare. Supporters of the bill, which includes many healthcare professionals and patient advocacy groups, commend its potential to modernize insurance practices and improve patient care. However, challenges do exist, particularly regarding the implementation of coverage guidelines and the need for insurers to comply with the new regulations without causing disruptions to existing care processes.

Contention

Despite the positive outlook, there are points of contention regarding the bill's implementation. Some stakeholders express concerns over how insurers will interpret the coverage requirements and whether there will be adequate mechanisms in place for patients to dispute denials of biomarker testing coverage. The potential for varied insurer responses could create inconsistencies in patient access and care, which advocates worry could undermine the bill's objectives. Addressing these issues will be critical for the successful rollout and effectiveness of HB 180.

Companion Bills

No companion bills found.

Previously Filed As

KY S0154

An act relating to health insurance coverage for biomarker testing

KY H0136

An act relating to health insurance coverage for biomarker testing

KY SB120

Relative to insurance coverage for biomarker testing.

KY HB1110

Health-care Coverage For Biomarker Testing

KY SB124

Health-Care Coverage for Biomarker Testing

KY H0532

An act relating to health insurance coverage for biomarker testing

KY H0885

Coverage for Biomarker Testing

KY HB4753

Relating to providing health insurance coverage concerning biomarker testing

KY SB0273

Biomarker testing coverage.

KY S2201

Accident And Sickness Insurance Policies -- Biomarker Testing Coverage

Similar Bills

No similar bills found.